A study has found that sirolimus-coated balloons vs thin drug-eluting stents in in-stent restenosis show similar favorable clinical outcomes.

The stent coatings can be broadly classified into three types: biocompatible coatings, drug-delivery coatings and polymer-free coatings/surfaces. Since metallic stent platforms will release ions ...

Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

The vascular stent market is segmented by technology into covered stents, drug-eluting stents, bare metal stents, and bioabsorbable stents. As of 2023, drug-eluting stents hold the largest market ...

bioabsorbable stents, and drug-eluting stents. These stents can be further divided into balloon-expandable and self-expanding types, depending on the deployment mechanism. Report coverage ...

As of 2023, drug-eluting stents hold the largest market share due to their clinical benefits, including a lower incidence of restenosis. These stents are coated with medication that helps prevent ...

did not outshine standard treatment with second generation drug-eluting stents (DES) as they were expected to, in a surprise finding of the first randomized trial to compare clinical outcomes in ...

Elutia (Nasdaq:ELUT) announced the first-ever patient implant of its EluPro drug-eluting biologic envelope cleared by the FDA ...

Drug-coated balloon (DCB) angioplasty as the initial strategy for de novo coronary artery stenoses didn't measure up to ...